<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04743193</url>
  </required_header>
  <id_info>
    <org_study_id>2020-514-169-13</org_study_id>
    <nct_id>NCT04743193</nct_id>
  </id_info>
  <brief_title>Different Low-flow Sevoflurane Anesthesia Techniques</brief_title>
  <official_title>Comparison of the Consumption of Sevoflurane in Two Different Concentrations and Two Different Currents During the Initial Period of Anesthesia in Patients Undergoing General Anesthesia With Minimal Flow</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kocaeli Derince Education and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kocaeli Derince Education and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      After reaching 1 MAC level with 4 lt / min fresh gas flow and 2.5% sevoflurane concentration&#xD;
      in the initial stage in 35 patients, anesthesia maintenance will be continued with 0.5 lt /&#xD;
      min fresh gas flow and 2 -4% sevoflurane concentration with the target of 1 MAC. For 35&#xD;
      patients, after reaching 1 (MAC) level with 1 lt / min fresh gas flow and 8% sevoflurane&#xD;
      concentration in the initial phase, maintenance of anesthesia will be continued with 0.5 lt /&#xD;
      min fresh gas flow and 2 -4% sevoflurane concentration, targeting 1 MAC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim of this study is to compare the instantaneous and total consumption of&#xD;
      sevoflurane using 2 different concentrations and different minute / fresh gas flow to fill&#xD;
      the system in the initial phase of anesthesia. Its secondary purpose is to compare the depth&#xD;
      of anesthesia and hemodynamic parameters between the two groups.&#xD;
&#xD;
      A total of 70 patients between the ages of 18-65 will be included in the study.in 2.5 %&#xD;
      sevoflurane grup After reaching 1 MAC level with 4 lt / min fresh gas flow and 2.5%&#xD;
      sevoflurane concentration in the initial stage in 35 patients, anesthesia maintenance will be&#xD;
      continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration with the&#xD;
      target of 1 MAC. in sevoflurane 8 % group for 35 patients, after reaching 1 (MAC) level with&#xD;
      1 lt / min fresh gas flow and 8% sevoflurane concentration in the initial phase, maintenance&#xD;
      of anesthesia will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane&#xD;
      concentration with the target of 1 MAC. . The depth of anesthesia for both groups will be&#xD;
      measured by the Bispectral Index (BIS). BIS values between 40 and 60 are appropriate values&#xD;
      for general anesthesia, for this value 1 MAC sevoflurane inhalation anesthesia and&#xD;
      remifentanil infusion (0.1-0.3mcg / kg / min) will be used.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 5, 2021</start_date>
  <completion_date type="Actual">May 15, 2021</completion_date>
  <primary_completion_date type="Actual">April 28, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>sevoflurane versus desflurane</measure>
    <time_frame>the study will comlete in one month</time_frame>
    <description>To compare the instant and total consumption of sevoflurane using 2 different concentrations and different minute / fresh gas flow to fill the system in the initial phase of anesthesia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>sevoflurane</measure>
    <time_frame>studdy will complete in one month</time_frame>
    <description>Its secondary purpose is to compare the depth of anesthesia and hemodynamic parameters between the two groups.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>sevoflurane 8 %</arm_group_label>
    <description>In the initial phase, after reaching 1 (MAK) level with 1lt / min fresh gas flow and 8% sevoflurane concentration, anesthesia maintenance will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration with the target of 1 MAC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sevoflurane 2.5 %</arm_group_label>
    <description>In the initial phase, after reaching 1 MAK level with 4 lt / min fresh gas flow and 2.5% sevoflurane concentration, anesthesia maintenance will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration with the target of 1 MAC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>2.5 %sevoflurane</intervention_name>
    <description>for 35 patients after reaching 1 MAK level with 4 lt / min fresh gas flow and 2,5% sevoflurane concentration in the initial phase, maintenance of anesthesia will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration with the target of 1 minimum alveolar concentration</description>
    <arm_group_label>sevoflurane 2.5 %</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>8% sevoflurane low flow anesthesia</intervention_name>
    <description>For 35 patients after reaching 1 (MAC) level with 1 lt / min fresh gas flow and 8% sevoflurane concentration in the initial phase, maintenance of anesthesia will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration, targeting 1 MAC. .</description>
    <arm_group_label>sevoflurane 8 %</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  Patients between the ages of 18-65&#xD;
&#xD;
          -  ASA1,2,3 group patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients between the ages of 18-65&#xD;
&#xD;
          -  ASA1,2,3 group patients&#xD;
&#xD;
          -  Patients under general anesthesia&#xD;
&#xD;
          -  Patients scheduled for elective surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient's refusal to participate in the study&#xD;
&#xD;
          -  Patients with less than 90 minutes of total anesthesia time&#xD;
&#xD;
          -  Patients whose total anesthesia time exceeds 180 minutes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Tahsin Şimşek</name>
      <address>
        <city>İstanbul</city>
        <state>Kartal</state>
        <zip>34000</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 2, 2021</study_first_submitted>
  <study_first_submitted_qc>February 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2021</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kocaeli Derince Education and Research Hospital</investigator_affiliation>
    <investigator_full_name>Tahsin Şimşek</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>inhalation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

